Piper Sandler Initiates Coverage On NeoGenomics with Overweight Rating, Announces Price Target of $13

Piper Sandler analyst David Westenberg initiates coverage on NeoGenomics (NASDAQ:NEO) with a Overweight rating and announces Price Target of $13.